Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Patient and Investigator-Blinded, Placebo-Controlled Proof-Of-Concept Study to Determine the Safety, Tolerability and Central Nervous System (CNS) Exposure of Oral RTB101 and Sirolimus Alone or in Combination in Patients with Mild-Moderate Parkinson's Disease (PD)

Next Previous
Trial Profile

A Multicenter, Patient and Investigator-Blinded, Placebo-Controlled Proof-Of-Concept Study to Determine the Safety, Tolerability and Central Nervous System (CNS) Exposure of Oral RTB101 and Sirolimus Alone or in Combination in Patients with Mild-Moderate Parkinson's Disease (PD)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dactolisib (Primary) ; Sirolimus (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors resTORbio

Most Recent Events

  • 07 May 2020 According to a resTORbio media release, the company plans to analyze the data from the four completed dosing arms and data from the four completed cohorts is expected by mid-2020.
  • 07 May 2020 Status changed from recruiting to discontinued, according to a resTORbio media release. To ensure safety of the clinical trial participants and the study coordinators, resTORbio has decided to terminate the study and not to enroll the fifth cohort due to the COVID-19 level 4 alert in New Zealand.
  • 03 Apr 2020 According to a resTORbio media release, the company have postponed enrollment in the fifth cohort due to COVID-19 level 4 alert in New Zealand. Enrollment in the first four cohorts has been completed

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top